CN112587437A - Composition containing carnosine and eye cream containing composition - Google Patents
Composition containing carnosine and eye cream containing composition Download PDFInfo
- Publication number
- CN112587437A CN112587437A CN202011429491.3A CN202011429491A CN112587437A CN 112587437 A CN112587437 A CN 112587437A CN 202011429491 A CN202011429491 A CN 202011429491A CN 112587437 A CN112587437 A CN 112587437A
- Authority
- CN
- China
- Prior art keywords
- parts
- carnosine
- palmitoyl
- composition
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 title claims abstract description 71
- 108010087806 Carnosine Proteins 0.000 title claims abstract description 71
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229940044199 carnosine Drugs 0.000 title claims abstract description 71
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000006071 cream Substances 0.000 title claims abstract description 15
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 43
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 9
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 9
- 239000011570 nicotinamide Substances 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- XCEMXBAGNZCOHW-JPZUFNMASA-N (2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 XCEMXBAGNZCOHW-JPZUFNMASA-N 0.000 claims description 14
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 9
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 9
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 9
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 9
- 229940025878 hesperidin Drugs 0.000 claims description 9
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 9
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 9
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000002518 antifoaming agent Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 23
- 210000002615 epidermis Anatomy 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000002776 aggregation Effects 0.000 abstract description 2
- 238000004220 aggregation Methods 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract description 2
- 238000004925 denaturation Methods 0.000 abstract description 2
- 230000036425 denaturation Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000002780 melanosome Anatomy 0.000 abstract description 2
- 238000013508 migration Methods 0.000 abstract description 2
- 230000005012 migration Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 238000007788 roughening Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 34
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 34
- 229940048851 cetyl ricinoleate Drugs 0.000 description 33
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 32
- 238000010438 heat treatment Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 20
- 229920002125 Sokalan® Polymers 0.000 description 20
- 229960001631 carbomer Drugs 0.000 description 20
- 229910003460 diamond Inorganic materials 0.000 description 19
- 239000010432 diamond Substances 0.000 description 19
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 19
- 238000002156 mixing Methods 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 18
- 229920002385 Sodium hyaluronate Polymers 0.000 description 17
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 17
- 241001135917 Vitellaria paradoxa Species 0.000 description 17
- 229940108690 glucosyl hesperidin Drugs 0.000 description 17
- 229940119170 jojoba wax Drugs 0.000 description 17
- 229940057910 shea butter Drugs 0.000 description 17
- 229940010747 sodium hyaluronate Drugs 0.000 description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 17
- 239000010497 wheat germ oil Substances 0.000 description 17
- 229930003427 Vitamin E Natural products 0.000 description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 16
- 229940046009 vitamin E Drugs 0.000 description 16
- 235000019165 vitamin E Nutrition 0.000 description 16
- 239000011709 vitamin E Substances 0.000 description 16
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 12
- -1 glycosyl hesperidin Chemical compound 0.000 description 11
- 229920002545 silicone oil Polymers 0.000 description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 9
- 239000004475 Arginine Substances 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 229960005323 phenoxyethanol Drugs 0.000 description 9
- GORMSINSWZJIKL-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-dimethylpropyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(C)(C)COC(=O)C(CC)CCCC GORMSINSWZJIKL-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 229940008099 dimethicone Drugs 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 description 5
- 235000002673 Dioscorea communis Nutrition 0.000 description 5
- 241000544230 Dioscorea communis Species 0.000 description 5
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 5
- 208000035753 Periorbital contusion Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the field of cosmetics and discloses a composition containing carnosine and eye cream containing the same. The composition comprises the following components: carnosine, palmitoyl polypeptide, nicotinamide, and a solvent. The invention adopts the combination of carnosine, palmitoyl polypeptide and nicotinamide to remove dark eye circles and improve the skin state of eyes. Inhibiting the production of AGEs by using carnosine, and combining with the formed AGEs to inactivate the AGEs; inhibiting melanosome migration to the skin surface using niacinamide; the palmitoyl polypeptide is used for regulating mature differentiation of epidermis, preventing aggregation and denaturation of protein, and preventing roughening of skin surface. The eye cream containing the composition can effectively improve long-term dark circles and prevent the aging of eye skin.
Description
Technical Field
The invention belongs to the field of cosmetics, and particularly relates to a composition containing carnosine and eye cream containing the composition.
Background
Dark circles refer to the phenomenon of even pigmentation in the infraorbital areas on both sides, and are generally dark black or dark brown. The eye skin is one of the thinnest skin of the human body, the thickness of the eye skin is only one third to one fifth of the thickness of the face skin, and the excessively thin dermal layer lacks elastic fibers and collagen structures and is easy to lose elasticity and become loose. Meanwhile, a high density of nerve fibers and capillaries are distributed around the eye, and a high frequency of movement (blinking) is required. When the daily work and rest is irregular, the fatigue is excessive or the injury is caused, the blood circulation is not smooth to cause the congestion, and the dim eyes and the pigmentation can be caused. With the increase of age, the metabolism of the body is gradually slowed down, the replacement time of the cells formed by the horny layer in the epidermis is prolonged, and the contents of natural moisturizing factors, ceramide and the like are reduced; the regeneration of collagen fibers in the dermis is not obvious, the content of hyaluronic acid is reduced, the water content is reduced, and the eye skin is dull and has no transparent feeling.
The existence of the black eye can lead people to look unsound and also influence the aesthetic feeling, and a plurality of beauty lovers are troubled. Therefore, cosmetics that can effectively remove dark circles have a great market demand. Although the eye cream on the market is more at present, the eye cream specially aims at removing black eye circles, has less eye cream with excellent effect and cannot meet the market demand.
Therefore, it is highly desirable to provide an eye cream capable of effectively removing dark circles.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art described above. Therefore, the invention provides a composition containing carnosine, which can effectively remove dark eye circles. The invention also provides an eye cream containing the composition.
A carnosine-containing composition comprising the following components: carnosine, palmitoyl polypeptide, nicotinamide, and a solvent.
Preferably, the palmitoyl polypeptide is palmitoyl tetrapeptide and palmitoyl tripeptide.
Further preferably, the palmitoyl polypeptide is selected from at least one of palmitoyl tetrapeptide-10, palmitoyl tetrapeptide-7, palmitoyl tripeptide-3, palmitoyl tripeptide-1, or palmitoyl tripeptide-8.
More preferably, the palmitoyl polypeptide is palmitoyl tetrapeptide-10 and palmitoyl tripeptide-8; most preferably, the mass ratio of the palmitoyl tetrapeptide-10 to the palmitoyl tripeptide-8 is (1-2): 1.
Preferably, the carnosine-containing composition comprises the following components in parts by weight: 0.3-1.5 parts of carnosine, 0.2-1.5 parts of palmitoyl polypeptide, 1-5 parts of nicotinamide and 50-70 parts of solvent.
Further preferably, the carnosine-containing composition comprises the following components in parts by weight: 0.3-1.2 parts of carnosine, 0.5-1 part of palmitoyl polypeptide, 3-5 parts of nicotinamide and 50-63 parts of solvent.
Preferably, the composition containing carnosine also comprises hesperidin, wherein the hesperidin accounts for 0.1-1 part; further preferably, the hesperidin is 0.5-1 part.
Preferably, the hesperidin is glycosyl hesperidin; further preferably, the hesperidin is glucosyl hesperidin. Hesperidin has effects in protecting and improving blood microcirculation, promoting telangiectasia and blood circulation, improving the resistance of fragile capillary to vascular penetration, and promoting fat excretion.
Preferably, the composition further comprises an adjuvant selected from at least one of an emulsifier, an antioxidant, an emollient, an antifoaming agent, a thickener, a humectant, a preservative, or a pH adjuster.
Preferably, the auxiliary agent is 10-30 parts; further preferably, the auxiliary agent is 12-25 parts. The content of the preservative in the auxiliary agent accounts for less than 1% of the total mass of the composition. The addition amount of each component in the auxiliary agent meets the requirement of the cosmetic industry standard.
Preferably, the emulsifier is at least one selected from glycerol stearate (a165), cetearyl glucoside, arachidyl glucoside and behenyl glucoside.
Preferably, the antioxidant is selected from at least one of vitamin E, tocopherol acetate, superoxide dismutase or glutathione peroxidase.
Preferably, the emollient is selected from at least one of jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethylhexanoate) ester (DONPG), or shea butter.
Preferably, the defoaming agent is selected from dimethyl silicone oil or silicone oil.
Preferably, the thickener is selected from at least one of carbomer, cellulose or xanthan gum.
Preferably, the humectant is at least one of 1, 3-propylene glycol, sodium hyaluronate, glycerin, polyethylene glycol or butylene glycol.
Preferably, the preservative is selected from benzyl alcohol and/or phenoxyethanol.
Preferably, the pH adjusting agent is arginine.
Preferably, the composition further comprises carbomer, gold foil, diamond powder. The carbomer gold foil and the diamond powder can enhance the synergistic effect of the carnosine, the palmitoyl polypeptide and the nicotinamide.
In a second aspect the invention provides a method for the preparation of a carnosine-containing composition.
Specifically, the preparation method of the composition containing the carnosine comprises the following steps:
and stirring and dissolving the components to prepare the composition containing the carnosine.
Further preferably, the preparation method of the carnosine-containing composition comprises the following steps:
(1) heating and mixing emulsifier, emollient, defoamer and antioxidant to prepare phase A;
(2) adding thickener, humectant, carbomer, gold foil, and diamond powder into solvent, heating and mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) heating and dissolving carnosine, palmitoyl polypeptide, nicotinamide, hesperidin and the rest components in water bath, adding into the phase C, homogenizing, and stirring to obtain the composition containing carnosine.
Preferably, the temperature for heating and mixing in the step (1) and the step (2) is 75-85 ℃; further preferably 75 to 80 ℃.
Preferably, the water bath heating temperature in the step (3) is below 40 ℃; further preferably 30 to 40 ℃.
In a third aspect of the invention, a cosmetic is provided comprising the carnosine-containing composition.
An eye cream comprising the carnosine-containing composition.
The invention also provides an application of the composition in preparing cosmetics.
Compared with the prior art, the invention has the following beneficial effects:
the invention adopts the combination of carnosine, palmitoyl polypeptide and nicotinamide to remove dark eye circles and improve the skin state of eyes. Using carnosine to inhibit the generation of AGEs (advanced glycosylation end products) and combine with formed AGEs to inactivate the AGEs; inhibiting melanosome migration to the skin surface using niacinamide; the palmitoyl polypeptide, especially palmitoyl tetrapeptide-10, is used for regulating mature differentiation of epidermis, recovering the steady state of skin, preventing aggregation and denaturation of protein, preventing roughening of the skin surface, and naturally restoring skin cell permeability. The synergistic effect of the three components can effectively improve long-term dark eye circles and prevent the aging of eye skin.
Detailed Description
In order to make the technical solutions of the present invention more apparent to those skilled in the art, the following examples are given for illustration. It should be noted that the following examples are not intended to limit the scope of the claimed invention.
The starting materials, reagents or apparatuses used in the following examples are conventionally commercially available or can be obtained by conventionally known methods, unless otherwise specified.
Example 1: method for preparing composition containing carnosine
A carnosine-containing composition comprising the following components: 0.8 part of carnosine, 0.8978 part of palmitoyl tetrapeptide-100.45 part, 80.3 parts of palmitoyl tripeptide, 4 parts of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of glyceryl stearate (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) dissolving carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C under heating, adding phase C, homogenizing, and stirring to obtain composition containing carnosine.
Example 2: method for preparing composition containing carnosine
A carnosine-containing composition comprising the following components: 0.8 part of carnosine, 0.8978 part of palmitoyl tetrapeptide-100.45 part, 30.3 parts of palmitoyl tripeptide, 4 parts of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of glyceryl stearate (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) dissolving carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-3, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C under heating, adding phase C, homogenizing, and stirring to obtain composition containing carnosine.
Example 3: method for preparing composition containing carnosine
A carnosine-containing composition comprising the following components: 0.8 part of carnosine, 100.65 parts of palmitoyl tetrapeptide, 80.1 parts of palmitoyl tripeptide, 4 parts of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of stearin (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) dissolving carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C under heating, adding phase C, homogenizing, and stirring to obtain composition containing carnosine.
Example 4: method for preparing composition containing carnosine
A carnosine-containing composition comprising the following components: 1.5 parts of carnosine, 100.5 parts of palmitoyl tetrapeptide, 80.3 parts of palmitoyl tripeptide, 1 part of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of stearin (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) dissolving carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C under heating, adding phase C, homogenizing, and stirring to obtain composition containing carnosine.
Example 5: method for preparing composition containing carnosine
A carnosine-containing composition comprising the following components: 0.2 part of carnosine, 100.8 parts of palmitoyl tetrapeptide, 80.4 parts of palmitoyl tripeptide, 2 parts of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of stearin (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) dissolving carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C under heating, adding phase C, homogenizing, and stirring to obtain composition containing carnosine.
Comparative example 1
A carnosine-containing composition comprising the following components: 2.8 parts of carnosine, 101.5 parts of palmitoyl tetrapeptide, 81.2 parts of palmitoyl tripeptide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of glyceryl stearate (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of dimethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) heating carnosine, palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, glucosyl hesperidin and the rest components in water bath at 40 deg.C for dissolving, adding phase C, homogenizing, and stirring to obtain carnosine-containing composition.
Comparative example 2
A composition comprising the following components: palmitoyl tetrapeptide-100.85 parts, palmitoyl tripeptide-80.5 parts, nicotinamide 4.2 parts, glucosyl hesperidin 0.5 part, deionized water 57 parts, glyceryl stearate (A165)3 parts, vitamin E0.5 part, jojoba oil 3 parts, wheat germ oil 3 parts, Cetyl Ricinoleate (CR)6 parts, neopentyl glycol di (ethyl hexanoate) 1 part, shea butter 5 parts, dimethicone 0.5 part, carbomer 0.5 part, 1, 3-propylene glycol 2 parts, sodium hyaluronate 2 parts, gold foil 2 parts, diamond powder 0.001 part, arginine 0.5 part, and phenoxyethanol 0.3 part.
A method of preparing a composition comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) heating palmitoyl tetrapeptide-10, palmitoyl tripeptide-8, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C for dissolving, adding phase C, homogenizing, and stirring to obtain composition.
Comparative example 3
A carnosine-containing composition comprising the following components: 1.5 parts of carnosine, 4 parts of nicotinamide, 0.5 part of glucosyl hesperidin, 57 parts of deionized water, 3 parts of stearin (A165), 0.5 part of vitamin E, 3 parts of jojoba oil, 3 parts of wheat germ oil, 6 parts of Cetyl Ricinoleate (CR), 1 part of neopentyl glycol di (ethyl hexanoate), 5 parts of shea butter, 0.5 part of simethicone, 0.5 part of carbomer, 2 parts of 1, 3-propylene glycol, 2 parts of sodium hyaluronate, 2 parts of gold foil, 0.001 part of diamond powder, 0.5 part of arginine and 0.3 part of phenoxyethanol.
A method for preparing a carnosine-containing composition, comprising the steps of:
(1) heating stearin, vitamin E, jojoba oil, wheat germ oil, Cetyl Ricinoleate (CR), neopentyl glycol di (ethyl hexanoate) ester, shea butter, and dimethyl silicone oil to 80 deg.C, and mixing to obtain phase A;
(2) adding carbomer, 1, 3-propylene glycol, sodium hyaluronate, gold foil and diamond powder into water, heating to 80 deg.C, mixing to obtain phase B, adding phase B into phase A, stirring, and homogenizing to obtain phase C;
(3) heating carnosine, nicotinamide, glucosyl hesperidin and the rest components in water bath at 40 deg.C for dissolving, adding phase C, homogenizing, and stirring to obtain carnosine-containing composition.
Product effectiveness testing
The carnosine-containing compositions prepared in examples 1 to 5 and comparative examples 1 to 3 were prepared into eye creams by a conventional method, respectively. 24 subjects aged between 25-35 were then organized for efficacy testing. The subjects were randomly divided into 8 groups of 3 persons each, and the effect of removing dark circles was tested with one eye cream per group, and the specific groups are shown in table 1. The test conditions were: keeping the temperature at 25 ℃ and the humidity at 40-60%; after the subjects cleaned their faces with warm water, they started the test after resting for 0.5-1h in a constant temperature and humidity room. Selecting the lower eyelid and external canthus of the tested person, slightly massaging from the inner side to the outer side in the direction along the texture of the skin of the eye, insisting on using once every day, and performing test and self-evaluation after 0-28 days of use. The skin quality, brightness of the skin was tested using the C-Cube multifunctional skin imaging analysis system from PIXIENCE, Inc., and the testers were self-rated for periocular skin gloss and black eye rating. The test results are shown in Table 1.
TABLE 1
Note: the L value represents luminance, where completely dark (L ═ 0) to absolutely white (L ═ 100);
ITA ° (individual type angle) represents skin tone: less than 10 deg. is brown, 10-28 deg. is brown, 28-41 deg. is normal color, 41-55 deg. is white, and more than 55 deg. is very white.
As can be seen from Table 1, the L value and ITA DEG of the eye skin of the testers of the eye cream prepared by using the compositions of examples 1-5 are obviously increased, which indicates that the skin at the black eye part is brighter and whiter, and the composition containing the carnosine has the effects of lightening the black eye and improving the skin color of the eye part; and the effects of examples 1-5 are significantly better than those of comparative examples 1-3.
Claims (10)
1. A carnosine-containing composition comprising the following components: carnosine, palmitoyl polypeptide, nicotinamide, and a solvent.
2. The composition of claim 1, wherein the palmitoyl polypeptide is selected from at least one of palmitoyl tetrapeptide-10, palmitoyl tetrapeptide-7, palmitoyl tripeptide-3, palmitoyl tripeptide-1, or palmitoyl tripeptide-8.
3. The composition of claim 2, wherein the palmitoyl polypeptides are palmitoyl tetrapeptide-10 and palmitoyl tripeptide-8; the mass ratio of the palmitoyl tetrapeptide-10 to the palmitoyl tripeptide-8 is (1-2): 1.
4. The composition according to claim 1, characterized by comprising the following components in parts by weight: 0.3-1.5 parts of carnosine, 0.2-1.5 parts of palmitoyl polypeptide, 1-5 parts of nicotinamide and 50-70 parts of solvent.
5. The composition according to claim 4, characterized in that it further comprises hesperidin in an amount of 0.1 to 1 part.
6. The composition of claim 1, further comprising an adjuvant selected from at least one of an emulsifier, an antioxidant, an emollient, an antifoaming agent, a thickener, a humectant, a preservative, or a pH adjuster.
7. A process for the preparation of a composition according to any one of claims 1 to 6, characterized in that it comprises the following steps:
and stirring and dissolving the components to prepare the composition.
8. An eye cream comprising the composition of any one of claims 1 to 6.
9. A cosmetic comprising the composition according to any one of claims 1 to 6.
10. Use of a composition according to any one of claims 1 to 6 for the preparation of a cosmetic product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011429491.3A CN112587437A (en) | 2020-12-09 | 2020-12-09 | Composition containing carnosine and eye cream containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011429491.3A CN112587437A (en) | 2020-12-09 | 2020-12-09 | Composition containing carnosine and eye cream containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112587437A true CN112587437A (en) | 2021-04-02 |
Family
ID=75191187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011429491.3A Pending CN112587437A (en) | 2020-12-09 | 2020-12-09 | Composition containing carnosine and eye cream containing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112587437A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
| CN110638707A (en) * | 2019-10-29 | 2020-01-03 | 浙江英树生物科技有限公司 | Eye care cream and preparation method thereof |
-
2020
- 2020-12-09 CN CN202011429491.3A patent/CN112587437A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
| CN110638707A (en) * | 2019-10-29 | 2020-01-03 | 浙江英树生物科技有限公司 | Eye care cream and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 珠海为你而美丽化妆品有限公司: "薄美克肌肽中肌提亮眼霜", 《国产非特殊用途化妆品备案服务平台》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5676956A (en) | Composition and method for reducing under-eye puffiness | |
| CN111529417B (en) | Repairing eye cream with blue light resisting effect and preparation method thereof | |
| CN110693807B (en) | Skin bottom essence and preparation method thereof | |
| CN113786376B (en) | Eye cream composition with eye pattern removing effect and preparation method thereof | |
| CN109602632A (en) | A kind of eye cream of the composition containing peptides and preparation method thereof | |
| CN113693962A (en) | Fibronectin-containing multiple protein repair composition and preparation method thereof | |
| CN113398016A (en) | Skin soothing and repairing composition and cosmetic composition | |
| CN111686068A (en) | Anti-wrinkle skin-activating cream and preparation method thereof | |
| CN108888539B (en) | Organic skin-care matrix, preparation method and application thereof, and organic cosmetic | |
| CN113576975A (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
| CN111991286A (en) | Eye cream composition for fading fine wrinkles and preparation method thereof | |
| CN114272172B (en) | Whitening and soothing composition and preparation method thereof | |
| CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
| CN113768853B (en) | Whitening and freckle-removing composition, and preparation method and application thereof | |
| CN106137785B (en) | A kind of regenerated skin care item of promotion skin repair | |
| CN113876661A (en) | Anti-aging composition for eyes and application thereof | |
| CN112494354A (en) | Composition containing acetyl tetrapeptide-5 and eye cream containing composition | |
| CN114632028B (en) | Lifting and tightening cream and preparation method thereof | |
| CN112587437A (en) | Composition containing carnosine and eye cream containing composition | |
| CN113786361B (en) | Eye cream composition with pouch removing effect and preparation method thereof | |
| CN114159333A (en) | Muscle foundation liquid and preparation method thereof | |
| CN111494287A (en) | Skin-whitening anti-aging beauty lotion composition Rufuyin and preparation method thereof | |
| CN112494384A (en) | Composition for removing dark eye circles, eye mask and preparation method of eye mask | |
| CN112603851A (en) | Composition containing ceramide and application of composition in eye cream | |
| CN115040467B (en) | Composition for relieving and resisting allergy, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210402 |
|
| RJ01 | Rejection of invention patent application after publication |